Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00966316

Acronym

PAIS

Enrollment

314

Registered

2009-08-26

Start date

2009-05-31

Completion date

2011-01-31

Last updated

2011-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

Acute Ischemic Stroke；clinical pathway;TCM；

Brief summary

The purpose of this study is to determine whether the clinical pathway for acute ischemic stroke(with combination of traditional Chinese medicine and western medicine) is able to improve the outcome of acute ischemic stroke and evaluate its effect on hospital day and cost, etc. Meanwhile, the study will discuss the safety and efficiency of this kind of Clinical Pathway

Detailed description

Eligibility Ages Eligible for Study: 18 Years to 85 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Those clinically diagnosed with acute ischemic stroke ； 18-85 years old； Over 6 hours and within 14 days from onset 4\<=NIHSS \<=22; Informed consent signed by patient or his/her family ； Exclusion Criteria: Hemorrhagic stroke; Cerebral hernia; Serious heart, liver, lung, kidney functional failure，malignancy; Not cooperative with physician; Psychological disorder; Already taken part in other clinical drug trial within the past 3 months

Interventions

DRUGaspirin，chinese herbs；

aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Ischemic stroke diagnosed with both criteria of traditional Chinese medicine and western medicine； * 18-85 years old； * Over 6 hours and within 14 days from onset * 4\<=NIHSS \<=22; * Informed consent signed by patient or his/her family ；

Exclusion criteria

* Hemorrhagic stroke; * Cerebral hernia; * Serious heart, liver, lung, kidney functional failure,malignancy; * Not cooperative with physician; * Psychological disorder; * Already taken part in other clinical drug trial within the past 3 months

Design outcomes

Primary

Measure	Time frame
death rate；average hospital day；cost of hospitalization	3 months；discharge day

Secondary

Measure	Time frame
Modified Rankin Scale (mRS) National Institute of Health Stroke Scale (NIHSS) Barthel Index degree of satisfaction	7 day；30 day；3 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026